ClinicalTrials.gg
CompletedNCT07874776Updated Oct 15, 2026

Effects of Three Carbohydrate Beverages on Resistance Training Performance

An interventional study of Dextrose and Maltodextrin in Resistance Training, Sports Nutrition and Dietary Carbohydrates, sponsored by Istanbul Gelisim University. Completed at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Istanbul Gelisim University · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2026, registered Sep 2026).
Updated Oct 15, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Sex
All
01

Study summary

This randomized, triple-blinded, counterbalanced crossover trial compared three carbohydrate beverages that provided the same amount of carbohydrate (30 g) but differed in carbohydrate source: dextrose, maltodextrin, and highly branched cyclic dextrin (HBCD). Resistance-trained adults completed a familiarization session, a one-repetition maximum (1RM) testing session, and three experimental sessions separated by at least 7 days. In each experimental session, participants ingested one of the beverages in three 10-g servings and performed five sets of up to 15 repetitions at 62.5% of 1RM in the squat, bench press, and bench pull. Mechanical performance, blood glucose and lactate, perceived exertion, and gastrointestinal symptoms were assessed during or immediately after exercise; perceived recovery and muscle soreness at 24 and 48 hours; and serum creatine kinase and cortisol at 48 hours.

Read the detailed description

Participants were randomly allocated (RANDOM.ORG) to the six possible sequences of the three beverages in a counterbalanced manner. The allocation sequence was generated before data collection by a researcher not involved in testing, data collection, or statistical analyses. The beverages were matched for taste, color, and volume by an external researcher from a professional food laboratory (Life Pro Nutrition, Madrid, Spain) and delivered in identical containers coded 911, 912, and 913; the key linking codes to beverages was held by this researcher until all statistical analyses had been completed. The total dose (30 g) was divided into three servings of 10 g, each dissolved in 100 mL of water, ingested 15 minutes after the warm-up (immediately before the squat) and immediately after the squat and bench press exercises. Participants arrived after a minimum 6-hour fast, maintained their habitual diet, avoided strenuous exercise for 48 hours, and refrained from caffeine or other stimulants for 8 hours before testing. Barbell velocity was recorded with a linear position transducer (GymAware RS). Capillary blood glucose and lactate were measured 90 seconds into the 5-minute rest after each exercise; venous blood for creatine kinase and cortisol was collected 48 hours after the session.

02

Conditions studied

  • Resistance Training
  • Sports Nutrition
  • Dietary Carbohydrates

Keywords

  • highly branched cyclic dextrin
  • maltodextrin
  • dextrose
  • carbohydrate supplementation
  • velocity-based training
  • blood glucose
  • cortisol
  • creatine kinase
03

In context

Lead sponsor

Istanbul Gelisim University is the lead sponsor of 63 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Student at the Faculty of Sports Sciences, Istanbul Gelisim University
  • Active participation in competitive sports
  • Regular resistance training
  • Prior experience with multi-joint resistance exercises
  • No musculoskeletal injuries during the six months preceding enrolment

Exclusion criteria

Exclusion Criteria:

  • Any acute or chronic disease
  • Current musculoskeletal injury
  • Any condition that could compromise safe participation in resistance exercise or influence performance, metabolic, or hormonal responses
  • Inability to perform the exercises safely and consistently with the prescribed technique during familiarization
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Dextrose

    Participants ingested 30 g of dextrose, divided into three 10-g servings each dissolved in 100 mL of water, during a standardized high-volume resistance training session (squat, bench press, bench pull; five sets of up to 15 repetitions at 62.5% of 1RM).

    Dietary Supplement: Dextrose

  • Experimental
    Maltodextrin

    Participants ingested 30 g of maltodextrin (DE15-18), divided into three 10-g servings each dissolved in 100 mL of water, during a standardized high-volume resistance training session (squat, bench press, bench pull; five sets of up to 15 repetitions at 62.5% of 1RM).

    Dietary Supplement: Maltodextrin

  • Experimental
    Highly Branched Cyclic Dextrin

    Participants ingested 30 g of highly branched cyclic dextrin (HBCD), divided into three 10-g servings each dissolved in 100 mL of water, during a standardized high-volume resistance training session (squat, bench press, bench pull; five sets of up to 15 repetitions at 62.5% of 1RM).

    Dietary Supplement: Highly Branched Cyclic Dextrin

Interventions

  • Dietary supplementDextrose

    Dextrose (Life Pro Nutrition, Madrid, Spain): 30 g in total, divided into three 10-g servings each dissolved in 100 mL of water, ingested 15 minutes after the warm-up (immediately before the squat) and immediately after the squat and bench press exercises. Matched for taste, color, and volume with the other beverages.

  • Dietary supplementMaltodextrin

    Maltodextrin DE15-18 (Sandek #150, Sanwa Starch Co., Ltd, Nara, Japan): 30 g in total, divided into three 10-g servings each dissolved in 100 mL of water, ingested 15 minutes after the warm-up (immediately before the squat) and immediately after the squat and bench press exercises. Matched for taste, color, and volume with the other beverages.

  • Dietary supplementHighly Branched Cyclic Dextrin

    Highly branched cyclic dextrin (Cluster Dextrin, Glico Nutrition Co., Ltd, Osaka, Japan): 30 g in total, divided into three 10-g servings each dissolved in 100 mL of water, ingested 15 minutes after the warm-up (immediately before the squat) and immediately after the squat and bench press exercises. Matched for taste, color, and volume with the other beverages.

06

What researchers measure

Primary outcomes

  1. Fastest Mean Concentric Velocity per Set (MVfastest)

    Fastest mean concentric barbell velocity (m/s) recorded within each of five sets of the squat, bench press, and bench pull, measured with a linear position transducer (GymAware RS), compared among the three beverage conditions.

    Time frame: From the first beverage serving (immediately before the squat) to completion of the bench pull, approximately 60 minutes, in each of the three experimental sessions

Secondary outcomes

  1. Number of Repetitions Completed per Set

    Number of repetitions completed in each of five sets (up to 15 repetitions at 62.5% of one-repetition maximum) of the squat, bench press, and bench pull, compared among the three beverage conditions.

    Time frame: From the first beverage serving (immediately before the squat) to completion of the bench pull, approximately 60 minutes, in each of the three experimental sessions

  2. Capillary Blood Glucose Concentration

    Fingertip capillary blood glucose concentration (mg/dL) measured with a portable glucose monitoring system (Contour Plus Elite).

    Time frame: 90 seconds into the 5-minute rest after the squat, bench press, and bench pull in each of the three experimental sessions

  3. Capillary Blood Lactate Concentration

    Fingertip capillary blood lactate concentration (mmol/L) measured with a portable lactate analyzer (Lactate Scout 4).

    Time frame: 90 seconds into the 5-minute rest after the squat, bench press, and bench pull in each of the three experimental sessions

  4. Rating of Perceived Exertion

    Perceived exertion rated on a modified 1-10 Rating of Perceived Exertion (RPE) scale; higher scores indicate greater exertion.

    Time frame: 5 minutes after completion of the resistance exercise protocol in each of the three experimental sessions

  5. Gastrointestinal Symptoms

    Stomach fullness, nausea, and abdominal cramping, each rated on an individual 1-10 scale.

    Time frame: 5 minutes after completion of the resistance exercise protocol in each of the three experimental sessions

  6. Perceived Recovery Status

    Perceived recovery rated on the 0-10 Perceived Recovery Status (PRS) scale; higher scores indicate better perceived recovery.

    Time frame: 24 hours and 48 hours after each of the three experimental sessions

  7. Muscle Soreness

    Muscle soreness rated on a 0-10 visual analogue scale (VAS); higher scores indicate greater soreness.

    Time frame: 24 hours and 48 hours after each of the three experimental sessions

  8. Serum Creatine Kinase Activity

    Serum creatine kinase activity (U/L) determined by an enzymatic method (cobas c 501 analyzer) from venous blood.

    Time frame: 48 hours after each of the three experimental sessions

  9. Serum Cortisol Concentration

    Serum cortisol concentration (µg/dL) determined by electrochemiluminescence immunoassay (cobas e 801 analyzer) from venous blood.

    Time frame: 48 hours after each of the three experimental sessions

07

Study locations

1 site
  • Istanbul Gelisim University, Faculty of Sports Sciences
    Istanbul, 34310, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data underlying the published results will be available from the corresponding author upon reasonable request.

Supporting information: Study protocol

Time frame: After publication of the study results.

Access criteria: Reasonable request to the corresponding author (Deniz Senturk, Istanbul Gelisim University).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jun 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 15, 2026
StartActual
May 4, 2026
Primary completionActual
Jun 8, 2026
CompletionActual
Jun 8, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874776
Lead sponsor
Istanbul Gelisim University
Responsible party
Deniz ŞENTÜRK (Professor, Istanbul Gelisim University) — Principal investigator
First posted
Oct 15, 2026
Start date
May 4, 2026
Primary completion
Jun 8, 2026
Completion
Jun 8, 2026
Last update
Oct 15, 2026

Study contacts

Deniz Şentürk, PhD
principal investigator · Istanbul Gelisim University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glucose · Maltodextrin

Start the discussion